论文部分内容阅读
目的探究盐酸美金刚治疗帕金森痴呆(PDD)患者的临床疗效。方法 86例帕金森痴呆患者,随机分为观察组和对照组,各43例。其中对照组均予以多巴丝肼治疗,观察组在此基础上予以盐酸美金刚治疗,观察对比两组临床疗效及药物不良反应。结果治疗后观察组蒙特利认知量表(Mo CA)和简易智能精神状态检查量表(MMSE)评分分别为(24.5±2.6)、(22.3±2.5)分,均高于对照组的(19.4±2.8)、(18.6±2.7)分(P<0.05);两组药物不良反应率分别为11.6%、16.3%,比较差异无统计学意义(P>0.05)。结论对帕金森痴呆患者予以盐酸美金刚治疗可进一步改善脑神经功能,且用药安全性较高。
Objective To investigate the clinical efficacy of memantine hydrochloride in patients with Parkinson’s dementia (PDD). Methods Eighty-six patients with Parkinson’s dementia were randomly divided into observation group and control group, with 43 cases in each. The control group were treated with dopplerizine, and the observation group was treated with memantine hydrochloride on this basis. The clinical efficacy and adverse drug reactions were compared between the two groups. Results After treatment, the scores of MoCA and MMSE in the observation group were (24.5 ± 2.6) and (22.3 ± 2.5) points higher than those in the control group (19.4 ± 2.8) and (18.6 ± 2.7) points respectively (P <0.05). Adverse drug reaction rates in the two groups were 11.6% and 16.3% respectively, with no significant difference (P> 0.05). Conclusions Memantine hydrochloride for patients with Parkinson’s dementia can further improve the neurological function of the brain and the medication is safe.